- Health Canada has authorized Moderna to begin a Phase I clinical trial of its mRNA vaccine candidate targeting Ebola disease caused by the Bundibugyo virus, making Canada the second country after the UK to approve clinical testing of the candidate
- The Phase I trial will evaluate the vaccine’s safety, dosage, and side effects in healthy volunteers. Participants will receive the vaccine candidate – not the virus – and researchers will assess whether it triggers an immune response against the Bundibugyo virus
- Moderna must successfully complete additional clinical trial phases before seeking Health Canada approval. Any future submission will undergo rigorous review for safety, efficacy, and quality before the vaccine can be marketed in Canada
- The authorization supports global Ebola preparedness and aligns with PHAC’s collaboration with Moderna to advance mRNA vaccine research and strengthen domestic vaccine manufacturing in Canada
Takeaways:
The main market signal is strategic rather than commercial: Health Canada’s clearance, alongside PHAC’s collaboration with Moderna, helps de-risk the company’s mRNA infectious-disease platform and can strengthen its standing as a partner for pandemic and outbreak response, while also supporting Canada’s domestic vaccine-research and manufacturing ambitions.
Source: CA Newswire
